Salmeterol Xinafoate

This page contains recent news articles, when available, and an overview of Salmeterol Xinafoate but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Overview:

Salmeterol Xinafoate (when available)

Pharmacology and use:
Salmeterol, a highly selective beta(2)-agonist, is used to treat asthma and to prevent bronchospasm in patients with reversible obstructive airway disease. For the treatment of Asthma and chronic obstructive pulmonary disease (COPD).

Mechanism Of Action:
Salmeterol's long, lipophilic side chain binds to exosites near beta(2)-receptors in the lungs and on bronchiolar smooth muscle, allowing the active portion of the molecule to remain at the receptor site, continually binding and releasing. Beta(2)-receptor stimulation in the lung causes relaxation of bronchial smooth muscle, bronchodilation, and increased bronchial airflow.

News Articles on Salmeterol

Article: Glaxo asthma drugs face safety review in America. - The...  -  Jul 13, 2005
SEREVENT(R) (salmeterol xinafoate) Inhalation ... by prescription in the United States. SEREVENT is marketed in the U.S. by Allen ... of Glaxo Inc. "The ... Pay-Per-View - Evening Standard - HighBeam Research

Seretide Accuhaler DPI - Fluticasone propionate, Salmeterol xinafoate...  -  Jan 2, 2008
Salmeterol xinafoate dilates the airways in the lungs to keep them open, allowing easier breathing. These effects can last up to 12 hours after the dose. ... Virtual Medical Centre - The Virtual Medical Centre

Seretide MDI - Fluticasone propionate and Salmeterol xinafoate -...  -  Feb 1, 2008
Seretide MDI contains two active medicines, fluticasone propionate and salmeterol xinafoate. These effects can last up to 12 hours after the dose. ... Virtual Medical Centre - The Virtual Medical Centre

… ; Seretide (fluticasone propionate/salmeterol xinafoate) is now...  -  May 11, 2006
SERETIDE metered dose inhaler (MDI) is now manufactured with a counter, which helps patients know how many doses they have left, making it the first MDI in ... Pay-Per-View - Pharmacy News - Factiva, from Dow Jones

Advair Diskus, Advair HFA, Brovana, Foradil, Serevent Diskus, and …  -  Nov 18, 2005
On March 2, 2006, FDA approved new safety labeling and Medication Guides for patients for Serevent Diskus (salmeterol xinafoate) and Advair Diskus ... FierceBiotech

Press Release: GSK Statement on FDA Proposed Labeling Change for …  -  Nov 18, 2005
SEREVENT(R) (salmeterol xinafoate) Inhalation ... by prescription in the United States. SEREVENT is marketed in the U.S. by Allen ... of Glaxo Inc. "The ... Pay-Per-View - PR Newswire - HighBeam Research

FDA advisory issued for three bronchodilators.(News)  -  Jun 1, 2006
The products with the new approved labeling and medication guides are Advair Diskus (fluticasone propionate with salmeterol xinafoate) and Serevent Diskus ... Free with registration - Pediatric News - AccessMyLibrary.com

Advair's Growth Could Be Hurt by FDA Labeling Proposal, Analysts Say  -  Nov 22, 2005
The FDA put Advair (fluticasone propionate/salmeterol xinafoate) on shaky ground late last week when it recommended that GSK update its existing product ... Pay-Per-View - Drug Industry Daily - Factiva, from Dow Jones

FDA Advisory Committee recommends continued availability of Serevent ...  -  Jul 20, 2005
The panel voted unanimously that GlaxoSmithKline's salmeterol, an active ingredient in Sereventо (salmeterol xinafoate) and Advair Diskus о (fluticasone ... Medical News Today - Medical News Today (press release)

FDA Advisory Committee recommends continued availability of Serevent ...  -  Jul 24, 2005
The panel voted unanimously that GlaxoSmithKline's salmeterol, an active ingredient in Serevent® (salmeterol xinafoate) and Advair Diskus ® (fluticasone ... i-newswire.com

Lung Med Linked To Heart Attack And Deaths  -  Sep 23, 2008
Salmeterol xinafoate, a long-acting beta(2)-adrenergic agonist, stimulates intracellular adenyl cyclase in catalyzing the conversion of adenosine ... Pharmalot

GSK statement on US Food and Drug Administration Pediatric Advisory …  -  Nov 29, 2007
Untreated and uncontrolled asthma is an urgent public health issue and Serevent® (salmeterol xinafoate) and Advair® (fluticasone propionate and salmeterol) ... webwire.com

GSK Receives Extended Licence Indication For Seretide In Europe …  -  Jul 16, 2007
Final Variation Assessment Report Seretide Diskus/Viani Diskus Seretide Evohaler/Viani Evohaler (fluticasone propionate/salmeterol xinafoate) ... Medical News Today - Medical News Today (press release)

Article: FDA panel supports two asthma bronchodilators.(News) - …  -  Sep 1, 2005
Dr. Harper of Charleston, S.C. Salmeterol is currently approved for use in patients ... the long-acting [beta]-agonist salmeterol xinafoate does not induce ... Pay-Per-View - Pediatric News - HighBeam Research

Pediatric Pharmacotherapy: For Health Care Professionals: Safety...  -  Mar 2, 2006
New labeling and Medication Guides were approved on March 2, 2006 for salmeterol xinafoate (Serevent Diskus ® ) and fluticasone propionate/ salmeteral ... Medscape

FDA recommends continued use of Serevent and Advair for asthma: GSK.  -  Aug 29, 2005
An advisory committee of the US Food and Drug Administration has recommended that GlaxoSmithKline's Serevent (salmeterol xinafoate) and Advair Diskus ... Pay-Per-View - Pharma Japan - Factiva, from Dow Jones

Significant Reduction In Rate Of Lung Function Decline Achieved In …  -  Aug 16, 2008
...[4] Final Variation Assessment Report Seretide Diskus/Viani Diskus Seretide Evohaler/Viani Evohaler (fluticasone proprionate/salmeterol xinafoate). ... Medical News Today - Medical News Today (press release)

Misleading Clinical Study May Bolster FACT Act, Consumer Group Claims  -  Oct 10, 2005
...a clinical study of its asthma drugs Serevent (salmeterol xinafoate) and Advair (fluticasone propionate/salmeterol xinafoate) to downplay their risks. ... Pay-Per-View - Drug Industry Daily - Factiva, from Dow Jones

GSK Announces Discontinuation Of Serevent MDI (Green Inhaler), …  -  Sep 28, 2007
GlaxoSmithKline Australia (GSK) has advised all pharmacists today that the Serevent (salmeterol xinafoate) Metered Dose Inhaler (MDI) will be discontinued ... Medical News Today - Medical News Today (press release)

Editorials - July 15, 2006 -- American Family Physician  -  Jul 15, 2006
FDA public health advisory: Serevent Diskus (salmeterol xinafoate inhalation powder), Advair Diskus (fluticasone propionate and salmeterol inhalation ... AAFP News Now

GSK Statement On US Food And Drug Administration Pediatric Advisory …  -  Dec 3, 2007
Untreated and uncontrolled asthma is an urgent public health issue and Serevent® (salmeterol xinafoate) and Advair® (fluticasone propionate and salmeterol) ... Medical News Today - Medical News Today (press release)

Allergists Respond to FDA Committee Recommendation on Asthma …  -  Dec 11, 2008
...fumarate dihydrate) but said Serevent (salmeterol xinafoate) and Foradil (formoterol fumarate) should no longer be used for treating asthma. ... International Business Times

Black box warnings: should you beware? Some medications carry the …  -  Sep 1, 2006
In March, the Food and Drug Administration (FDA) ruled that the asthma medications fluticasone propionate and salmeterol (Advair) and salmeterol xinafoate ... Free with registration - Focus on Healthy Aging - AccessMyLibrary.com

FDA Says Serevent Risk-Benefit Profile for Use in Kids Is Unfavorable  -  Nov 28, 2007
Serevent (salmeterol xinafoate), a long-acting beta agonist (LABA), has two pediatric asthma indications: the prevention of bronchospasm in patients 4 years ... FDA news - FDA news (subscription)

Retail drug sales up 5% in 2005.(retail pharmacies )  -  Apr 3, 2006
4) Plavix (clopidogrel), Bristol-Myers Squibb (USA) and Sanofi-Aventis (France); and 5) Seretide (salmeterol xinafoate), GlaxoSmithKline (UK). Free with registration - Pharma Marketletter - AccessMyLibrary.com

FDA Advisory Committee Wants Stronger Warning for Serevent  -  Nov 30, 2007
28 to discuss the safety of the drug after serious pediatric adverse events, including patient deaths, were reported for Serevent (salmeterol xinafoate) ... FDA news - FDA news (subscription)

Allergists Respond To FDA Committee Recommendation On Asthma …  -  Dec 15, 2008
...fumarate dihydrate) but said Serevent (salmeterol xinafoate) and Foradil (formoterol fumarate) should no longer be used for treating asthma. ... Medical News Today - Medical News Today (press release)

Drug sales up 5% in year to August 2007.(Financial report)  -  Oct 22, 2007
The top drugs chart showed: 1) Lipitor (atorvastatin), made by Pfizer; 2) Nexium (esomeprazole), AstraZeneca ; 3) Seretide (salmeterol xinafoate), GSK; ... Free with registration - Pharma Marketletter - AccessMyLibrary.com

A reality check on emerging markets.  -  Jul 1, 2008
...(esomeprazole magnesium), "Plavix" (clopidogrel bisulfate), "Seretide/Advair" (fluticasone propionate; salmeterol xinafoate), and "Enbrel" (etanercept). ... $20.00 - Pharmaceutical Technology - Alacra Store

Advair HFA.  -  Aug 7, 2006
GlaxoSmithKline, Research Triangle Park, N.C., (919) 483-2100, has received approval for Advair HFA (fluticasone propionate and salmeterol xinafoate ... $9.94 - Drug Topics - Alacra Store

FDA warns of long-acting bronchodilator risks.(Rx)  -  Dec 15, 2005
The three products that are available in the United States are formoterol fumarate inhalation powder (Foradil) and salmeterol xinafoate inhalation powder ... Free with registration - Internal Medicine News - AccessMyLibrary.com

Drug sales up 5% in year to July 2007.(Financial report)  -  Sep 24, 2007
The top five drugs were: 1) Lipitor (atorvastatin), made by Pfizer; 2) Nexium (esomeprazole), AstraZeneca ; 3) Seretide (salmeterol xinafoate), GSK; ... $4.95 - Pharma Marketletter - ECNext

Article: Advair use extended for COPD.(NEWS FROM THE FDA) - Internal ...  -  Jun 1, 2008
...combines 250 mcg of fluticasone propionate (a corticosteroid) with 50 mcg of salmeterol xinafoate (a long-acting [beta]-agonist). ... Pay-Per-View - Internal Medicine News - HighBeam Research

Advair HFA.(NEW DRUGS)(Brief article)  -  Aug 7, 2006
GlaxoSmithKline, Research Triangle Park, NC, (919) 483-2100, has received approval for Advair HFA (fluticasone propionate and salmeterol xinafoate ... $4.95 - Drug Topics - ECNext

Asthma Therapy; Salmeterol HFA and CFC inhalers have equivalent …  -  Jul 26, 2005
...randomized, parallel-group, double-blind studies were conducted to compare the safety and efficacy of salmeterol xinafoate delivered by an MDI using the ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones

Healthy Steps materials online.(FYI)(Healthy Steps for Young Children)...  -  Jan 1, 2006
Use of the long-acting [beta]-agonist salmeterol xinafoate does not induce arrhythmias or long QT intervals in young children, Dr. Thomas B. Harper said at ... Pay-Per-View - Pediatric News - HighBeam Research

Drug sales up 5% in year to September 2007.(Financial report)  -  Nov 26, 2007
The top drugs chart showed: 1) Lipitor (atorvastatin), made by Pfizer; 2) Nexium (esomeprazole), AstraZeneca; 3) Seretide (salmeterol xinafoate), GSK; ... $4.95 - Pharma Marketletter - ECNext

GlaxoSmithKline.(Update) | Article from Medical Marketing & Media | …  -  Sep 1, 2008
An interim analysis of a large safety study of GlaxoSmithKline's asthma drug Serevent (salmeterol xinafoate ... particularly in some patients," the FDA said ... Pay-Per-View - Medical Marketing & Media - HighBeam Research

Flutide, Serevent combination effective against paediatric asthma:...  -  Sep 25, 2006
Flutide (fluticasone propionate) and the long-acting inhalant B2 stimulant Serevent (salmeterol xinafoate) is effective in treating childhood asthma. ... Pay-Per-View - Pharma Japan - Factiva, from Dow Jones

Early UTI therapy fails to reduce renal scarring.(News) | Article...  -  Oct 1, 2008
Use of the long-acting [beta]-agonist salmeterol xinafoate does not induce arrhythmias or long QT intervals in young children, Dr. Thomas B. Harper said at ... Pay-Per-View - Pediatric News - HighBeam Research

Take a breather: Cath O'Driscoll goes in search of the perfect...  -  Sep 10, 2007
Early studies with the steroidal asthma drugs budesonide and fluticasone propionate and the long-acting beta-agonists (LABAs) salmeterol xinafoate and ... $4.95 - Chemistry and Industry - ECNext

Ozone Friendly Formulation, Flovent(R) HFA (Fluticasone Propionate …  -  Feb 7, 2005
Similar transitions occurred for Ventolin (albuterol sulfate inhalation aerosol), a short-acting bronchodilator, and Serevent (salmeterol xinafoate ... RedOrbit

Amgen and J&J can continue to market their anemia drugs for cancer …  -  Apr 1, 2008
Medical Marketing & Media; March 1, 2003 ; 700+ words ... ... of GlaxoSmithKline's asthma drug Serevent (salmeterol xinafoate) "suggests that the drug may ... Pay-Per-View - Medical Marketing & Media - HighBeam Research

GlaxoSmithKline.(Pipeline) | Article from Medical Marketing & Media |...  -  Nov 1, 2006
An interim analysis of a large safety study of GlaxoSmithKline's asthma drug Serevent (salmeterol xinafoate ... particularly in some patients," the FDA said ... Pay-Per-View - Medical Marketing & Media - HighBeam Research

GlaxoSmithKline.(Pipeline) | Article from Medical Marketing & Media |...  -  May 1, 2007
An interim analysis of a large safety study of GlaxoSmithKline's asthma drug Serevent (salmeterol xinafoate ... particularly in some patients," the FDA said ... Pay-Per-View - Medical Marketing & Media - HighBeam Research

Europe policy: Parallel disputes  -  Sep 21, 2008
...epilepsy) and Serevent (salmeterol xinafoate, asthma), supplying them directly to hospitals and pharmacies for a period of three months in 2000. ... $34.00 - EIU Country Analysis - Alacra Store

Asthma Drugs Should Remain on Market, But Foradil Needs Black Box, …  -  Jul 15, 2005
...(fluticasone propionate/salmeterol) and Serevent (salmeterol xinafoate inhalation powder) -- warrant the products remaining available to US consumers. ... Pay-Per-View - Drug Industry Daily - Factiva, from Dow Jones

World spending: Retail drug sales in year to August 2008  -  Oct 16, 2008
3) Plavix (clopidogrel), Bristol-Myers Squibb (USA) and Sanofi-Aventis; 4) Seretide/Advair (salmeterol xinafoate), GSK; and 5) Enbrel (etanercept), ... $34.00 - EIU Country Analysis - Alacra Store

Drug Delivery; Pharmaceutical company offers ozone-friendly inhalation...  -  Mar 8, 2005
Similar transitions occurred for Ventolin (albuterol sulfate inhalation aerosol), a short-acting bronchodilator, and Serevent (salmeterol xinafoate ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones

FDA advisory looks at long-acting bronchodilators; agency warns about...  -  Dec 15, 2005
The three products available in the United States are formoterol fumarate inhalation powder (Foradil) and salmeterol xinafoate inhalation powder (Serevent), ... Pay-Per-View - Family Practice News - HighBeam Research

В�?С въз�?танови дей�?твието на лекар�?твени�? �?пи�?ък на Здравнат  -  Sep 27, 2006
а�?тма между една и четиригодишна възра�?т и един�?твени�? дългодей�?тващ бронхоразширител от групата на бета2агони�?тите - Salmeterol xinafoate (Sereventtm). ... News.bg

Drug Delivery; Pharmaceutical company offers ozone-friendly inhalation...  -  Mar 7, 2005
Similar transitions occurred for Ventolin (albuterol sulfate inhalation aerosol), a short-acting bronchodilator, and Serevent (salmeterol xinafoate ... Pay-Per-View - Biotech Business Week - Factiva, from Dow Jones

Drug Delivery; Pharmaceutical company offers ozone-friendly inhalation...  -  Mar 11, 2005
Similar transitions occurred for Ventolin (albuterol sulfate inhalation aerosol), a short-acting bronchodilator, and Serevent (salmeterol xinafoate ... Pay-Per-View - Drug Week - Factiva, from Dow Jones

GlaxoSmithKline.(Update) | Article from Medical Marketing & Media | …  -  Nov 1, 2005
An interim analysis of a large safety study of GlaxoSmithKline's asthma drug Serevent (salmeterol xinafoate ... particularly in some patients," the FDA said ... Pay-Per-View - Medical Marketing & Media - HighBeam Research

New bronchodilator joins group of environmentally friendly agents.(Rx)...  -  Mar 15, 2005
Foradil has not been directly compared with Serevent (salmeterol xinafoate inhalation aerosol), the first long-acting [[beta].sub.2]-agonist approved in ... Pay-Per-View - Internal Medicine News - HighBeam Research

FDA warns of long-acting bronchodilator risks.(Rx) | Article from...  -  Dec 15, 2005
The three products that are available in the United States are formoterol fumarate inhalation powder (Foradil) and salmeterol xinafoate inhalation powder ... Pay-Per-View - Internal Medicine News - HighBeam Research

Safety of asthma drugs questioned.(Brief Article)  -  Jul 30, 2005
The FDA's pulmonary and allergy drugs advisory committee decided that three asthma products - Serevent (salmeterol xinafoate), Advair (salmeterol plus ... $4.95 - Chemist & Druggist - ECNext

Treating allergies & asthma.  -  Aug 1, 2005
...(salmeterol xinafoate), Foradil (formoterol), and Advair (combination of fluticasone and salmeterol). Theophylline. Relaxes bronchial airways. ... $4.95 - National Women's Health Report - ECNext

Bronchodilators, Adrenergic (Inhalation).  -  Feb 1, 2006
Salmeterol xinafoate with chlorofluorocarbons (CFCs) as an inhalation aerosol was voluntarily withdrawn from the U.S. market by GlaxoSmithKline on 06/2003. ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com

В�?С отхвърли жалбата за �?пиране на лекар�?твени�? �?пи�?ък  -  Nov 2, 2006
законови норми по отношение на не�?ъдържащите �?е в него лекар�?твени продукти Fluticasone propionate (Flixotidetm) и Salmeterol xinafoate (Sereventtm). ... mediapool.bg

全�?�主�?医�?�市场销售增长5个百分点  -  Aug 3, 2006
...克公�?�的辛�?他汀(simvastatin,舒�?之,Zocor)和葛兰素�?�克公�?�的羟�?�甲酸沙美特罗/ 丙酸氟替�?��?�(salmeterol xinafoate/fluticasone propionate,舒利迭,Seretide)。 �?��?

全�?�制�?�业�?�临�?所未有的冲击  -  Oct 8, 2005
...异维A酸（isotretinoin，Accutane）和�?�能致严�?哮喘患者死亡风险增大的哮喘和慢性阻塞性肺疾病用�?�希�?�酸沙美特罗�?�入剂（salmeterol xinafoate，Serevent）等。 ... 腾讯网

550亿美元索赔压垮默克  -  Sep 30, 2005
...用�?�异维A酸(isotretinoin，Accutane)和�?�能致严�?哮喘患者死亡风险增大的哮喘和慢性阻塞性肺疾病用�?�希�?�酸沙美特罗�?�入剂(salmeterol xinafoate，Serevent)等。 ... 新浪网

Bronchodilators, Adrenergic (Inhalation).  -  Jul 28, 2005
Salmeterol xinafoate with chlorofluorocarbons (CFCs) as an inhalation aerosol was voluntarily withdrawn from the U.S. market by GlaxoSmithKline on 06/2003. ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com

�?�료계 정론 메디�?�뉴스  -  Nov 30, 2007
...세레벤트는 GSK�?� 최대 천�? 치료약 어드베아(Advair) 주성분 Salmeterol xinafoate 를 함유한 �?�입형 약물로 작년�? FDA가 �? 약품 모�? 천�? 관련 사�?�?� 유발할 수 ... 메디�?�뉴스

Brand Names/Synonyms:
Salmeterol Xinafoate is also known by the following brand names and/or synonymsAeromax; Arial; Astmerole; CHEMBANK1801; SEREVENT; Salmetedur; Salmeterol; Salmeterol Xinafoate; Salmeterol [Usan:Ban:Inn]; Salmeterolum [Latin]; Serevent; [Usan:Ban:Inn]

Drug Category:
Salmeterol Xinafoate is categorized under the following by the FDA: Bronchodilator Agents; Sympathomimetic; Adrenergic beta-Agonists;

Dosage Forms:
METERED-DOSE (AEROSOL); POWDER

Absorption:
Because of the small therapeutic dose, systemic levels of salmeterol are low or undetectable after inhalation of recommended doses (50 mcg of salmeterol inhalation powder twice daily). Following chronic administration of an inhaled dose of 50 mcg of salmeterol inhalation powder twice daily, salmeterol was detected in plasma within 5 to 45 minutes in 7 patients with asthma; plasma concentrations were very low, with mean peak concentrations of 167 pg/mL at 20 minutes and no accumulation with repeated doses.

Interactions:
[an error occurred while processing this directive]

Chemical IUPAC Name:
2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]-phenol

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.